HC Wainwright Reiterates “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reissued by HC Wainwright in a report issued on Friday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Up 0.9 %

SXTP stock opened at $1.10 on Friday. The stock has a market capitalization of $2.53 million, a price-to-earnings ratio of -0.11 and a beta of 4.40. The stock’s fifty day simple moving average is $1.19 and its 200-day simple moving average is $0.98. 60 Degrees Pharmaceuticals has a 52-week low of $0.70 and a 52-week high of $13.20.

Insider Transactions at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow purchased 35,823 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average cost of $1.27 per share, with a total value of $45,495.21. Following the acquisition, the chief executive officer now owns 94,580 shares in the company, valued at approximately $120,116.60. This trade represents a 60.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders purchased 66,372 shares of company stock valued at $82,410 over the last quarter. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.